Résumé
Objective The aim of this study was to investigate the clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia.Methods 125 patients with MDS/AML were selected as the research subjects,and selected 20 healthy subjects as a healthy control group.The mRNA and protein ex-pression levels of CDKN1C in CD34 +cells of MDS/AML patients were analyzed.The expression levels of CDKN1C were compared with those of MDS patients.The survival rate of patients with MDS and AML was analyzed by Cox regression analysis.The survival rate of MDS patients with different expression levels of CDKN1C was also analyzed.Results The expression of CDKN1C at levels of mR-NA and protein in bone marrow CD34 +cells of MDS/AML patients were significantly higher than those in healthy controls(P <0.05).There has a positive correction with BM(P<0.05).The survival rate of CDKN1C high expression group was significantly low-er than that in the low and mediate CDKN1C expression groups(P<0.05).The results of Cox regression analysis showed that age, high BM count,cytogenetic difference and the positive expression of CDKN1C significantly affected the survival rate of patients with MDS/AML(P< 0.05);The survival rate of MDS/AML chemotherapy in the CDKN1C positive group was significantly lower than that of CDKN1C negative expression group(P<0.05).The survival rate of MDS/AML after chemotherapy AlloSCT CDKN1C positive ex-pression group was significantly lower than that of CDKN1C negative expression group(P<0.05).Conclusion The expression of CDKN1C in bone marrow of MDS/AML patients was significantly increased,and the positive expression of CDKN1C significantly in-creased,and the positive expression of CDKN1C significantly affected the survival rate of MDS/AML patients.
Résumé
Objective To investigate the expression of CDKN1C in bone marrow in myelodysplastic syndromes and clinical significance of the detection of syndrome and secondary acute myeloid leukemia patients.Methods 125 patients with MDS/ AML were selected as the research object,and selected 20 cases of healthy people as healthy control group,and to investigate the mRNA and protein expression in CD34+ cells in bone marrow the expression of MDS/AML in patients and the survival rate of different expression of CDKN1C,to analyze the factors for survival rate of patients with MDS by Cox regression,and analyze the different treatment methods in patients with MDS/AML.Results The expression lcvcls of CDKN1C mRNA and protein of bone marrow CD34 + cells in the patients with MDS/AML were significantly higher than the healthy control group (t=5.324,7.326;P=0.002,0.000),and which was positive with BM count (r=2.014,P=0.004);the survival rate of CDKN1C high expression levels in patients with MDS/AML was significantly lower than that of the low expression of CDKN1C group and intermediate CDKN1C expression group (P＜0.05).Cox regression analysis showed that age,high BM count,cytogenetic risk difference and CDKN1C positive significantly affect the survival rate of patients with MDS/AML (95％CI=1.10～1.32,1.92～4.40,1.18～2.67,1.03～2.32,P=0.034～0.000).MDS/AML chemotherapy in CDKN1C positive group was significantly lower than the survival rate of patients with CDKN1C negative expression group (t=5.314,P=0.002).Conclusion The expression of CDKN1C in bone marrow of patients with MDS/AML was significantly increased,and the high expression of CDKN1CMDS/AML effect of chemotherapy on the survival rate of patients with MDS/AML.